Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of a multifaceted educational intervention for anti-infectious measures on sepsis mortality: a cluster randomized trial.
Bloos F, Rüddel H, Thomas-Rüddel D, Schwarzkopf D, Pausch C, Harbarth S, Schreiber T, Gründling M, Marshall J, Simon P, Levy MM, Weiss M, Weyland A, Gerlach H, Schürholz T, Engel C, Matthäus-Krämer C, Scheer C, Bach F, Riessen R, Poidinger B, Dey K, Weiler N, Meier-Hellmann A, Häberle HH, Wöbker G, Kaisers UX, Reinhart K; MEDUSA study group. Bloos F, et al. Among authors: weyland a. Intensive Care Med. 2017 Nov;43(11):1602-1612. doi: 10.1007/s00134-017-4782-4. Epub 2017 May 2. Intensive Care Med. 2017. PMID: 28466151 Clinical Trial.
Adverse effects of delayed antimicrobial treatment and surgical source control in adults with sepsis: results of a planned secondary analysis of a cluster-randomized controlled trial.
Rüddel H, Thomas-Rüddel DO, Reinhart K, Bach F, Gerlach H, Lindner M, Marshall JC, Simon P, Weiss M, Bloos F, Schwarzkopf D; MEDUSA study group. Rüddel H, et al. Crit Care. 2022 Feb 28;26(1):51. doi: 10.1186/s13054-022-03901-9. Crit Care. 2022. PMID: 35227308 Free PMC article. Clinical Trial.
A multifaceted educational intervention improved anti-infectious measures but had no effect on mortality in patients with severe sepsis.
Schwarzkopf D, Matthaeus-Kraemer CT, Thomas-Rüddel DO, Rüddel H, Poidinger B, Bach F, Gerlach H, Gründling M, Lindner M, Scheer C, Simon P, Weiss M, Reinhart K, Bloos F; MEDUSA study group. Schwarzkopf D, et al. Sci Rep. 2022 Mar 10;12(1):3925. doi: 10.1038/s41598-022-07915-9. Sci Rep. 2022. PMID: 35273276 Free PMC article.
Hyperlactatemia is an independent predictor of mortality and denotes distinct subtypes of severe sepsis and septic shock.
Thomas-Rueddel DO, Poidinger B, Weiss M, Bach F, Dey K, Häberle H, Kaisers U, Rüddel H, Schädler D, Scheer C, Schreiber T, Schürholz T, Simon P, Sommerer A, Schwarzkopf D, Weyland A, Wöbker G, Reinhart K, Bloos F; Medical Education for Sepsis Source Control and Antibiotics Study Group. Thomas-Rueddel DO, et al. Among authors: weyland a. J Crit Care. 2015 Apr;30(2):439.e1-6. doi: 10.1016/j.jcrc.2014.10.027. Epub 2014 Oct 30. J Crit Care. 2015. PMID: 25466313
Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients With Severe Sepsis or Septic Shock: A Randomized Clinical Trial.
Bloos F, Trips E, Nierhaus A, Briegel J, Heyland DK, Jaschinski U, Moerer O, Weyland A, Marx G, Gründling M, Kluge S, Kaufmann I, Ott K, Quintel M, Jelschen F, Meybohm P, Rademacher S, Meier-Hellmann A, Utzolino S, Kaisers UX, Putensen C, Elke G, Ragaller M, Gerlach H, Ludewig K, Kiehntopf M, Bogatsch H, Engel C, Brunkhorst FM, Loeffler M, Reinhart K; for SepNet Critical Care Trials Group. Bloos F, et al. Among authors: weyland a. JAMA Intern Med. 2016 Sep 1;176(9):1266-76. doi: 10.1001/jamainternmed.2016.2514. JAMA Intern Med. 2016. PMID: 27428731 Clinical Trial.
Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis: The HYPRESS Randomized Clinical Trial.
Keh D, Trips E, Marx G, Wirtz SP, Abduljawwad E, Bercker S, Bogatsch H, Briegel J, Engel C, Gerlach H, Goldmann A, Kuhn SO, Hüter L, Meier-Hellmann A, Nierhaus A, Kluge S, Lehmke J, Loeffler M, Oppert M, Resener K, Schädler D, Schuerholz T, Simon P, Weiler N, Weyland A, Reinhart K, Brunkhorst FM; SepNet–Critical Care Trials Group. Keh D, et al. Among authors: weyland a. JAMA. 2016 Nov 1;316(17):1775-1785. doi: 10.1001/jama.2016.14799. JAMA. 2016. PMID: 27695824 Clinical Trial.
Fever and hypothermia represent two populations of sepsis patients and are associated with outside temperature.
Thomas-Rüddel DO, Hoffmann P, Schwarzkopf D, Scheer C, Bach F, Komann M, Gerlach H, Weiss M, Lindner M, Rüddel H, Simon P, Kuhn SO, Wetzker R, Bauer M, Reinhart K, Bloos F; MEDUSA study group. Thomas-Rüddel DO, et al. Crit Care. 2021 Oct 21;25(1):368. doi: 10.1186/s13054-021-03776-2. Crit Care. 2021. PMID: 34674733 Free PMC article. Clinical Trial.
Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study).
Bauer M, Weyland A, Marx G, Bloos F, Weber S, Weiler N, Kluge S, Diers A, Simon TP, Lautenschläger I, Gründling M, Jaschinski U, Simon P, Nierhaus A, Moerer O, Reill L, Jörres A, Guo R, Loeffler M, Reinhart K, Riedemann N. Bauer M, et al. Among authors: weyland a. Crit Care Explor. 2021 Nov 17;3(11):e0577. doi: 10.1097/CCE.0000000000000577. eCollection 2021 Nov. Crit Care Explor. 2021. PMID: 34806021 Free PMC article.
(1 → 3)-β-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial.
Bloos F, Held J, Kluge S, Simon P, Kogelmann K, de Heer G, Kuhn SO, Jarczak D, Motsch J, Hempel G, Weiler N, Weyland A, Drüner M, Gründling M, Meybohm P, Richter D, Jaschinski U, Moerer O, Günther U, Schädler D, Weiss R, Putensen C, Castellanos I, Kurzai O, Schlattmann P, Cornely OA, Bauer M, Thomas-Rüddel D; SepNet Study Group. Bloos F, et al. Among authors: weyland a. Intensive Care Med. 2022 Jul;48(7):865-875. doi: 10.1007/s00134-022-06733-x. Epub 2022 Jun 16. Intensive Care Med. 2022. PMID: 35708758 Free PMC article. Clinical Trial.
Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.
Brunkhorst FM, Oppert M, Marx G, Bloos F, Ludewig K, Putensen C, Nierhaus A, Jaschinski U, Meier-Hellmann A, Weyland A, Gründling M, Moerer O, Riessen R, Seibel A, Ragaller M, Büchler MW, John S, Bach F, Spies C, Reill L, Fritz H, Kiehntopf M, Kuhnt E, Bogatsch H, Engel C, Loeffler M, Kollef MH, Reinhart K, Welte T; German Study Group Competence Network Sepsis (SepNet). Brunkhorst FM, et al. Among authors: weyland a. JAMA. 2012 Jun 13;307(22):2390-9. doi: 10.1001/jama.2012.5833. JAMA. 2012. PMID: 22692171 Clinical Trial.
127 results